COMP <GO>
PFE vs ABT // GROSS PROFIT MARGIN
Pfizer Inc. (NYSE) VS. Abbott Laboratories (NYSE) • 15-METRIC TALLY: PFE 5
— ABT 9
▲ GROSS PROFIT MARGIN LEADER: PFE
LAST: $30.52 (+1.90%) • MKT CAP: $170.71B
gross-margins
74.30%
LAST: $106.20 (+1.56%) • MKT CAP: $180.95B
gross-margins
56.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PFE VS. ABT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PFE | ABT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 74.30% | 56.40% | +17.90 | PFE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.10% | 11.90% | -6.80 | ABT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.7x | 18.4x | +1.30 | ABT | /valuation <GO> |
| Free Cash Flow Yield | 5.32% | 4.09% | +1.23 | PFE | /fcf-yield <GO> |
| Operating Margin | 15.10% | 18.20% | -3.10 | ABT | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 14.70% | -2.30 | ABT | /net-margins <GO> |
| Revenue Growth (YoY) | -1.60% | 5.70% | -7.30 | ABT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.10 | 4.36 | -2.26 | ABT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | ABT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 54.2 | +4.30 | PFE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.99 | +0.06 | PFE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 25.8x | -5.30 | PFE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $170.71B | $180.95B | -$10.24B | ABT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PFE REV | ABT REV | PFE GROSS % | ABT GROSS % | PFE FCF | ABT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.58B | $44.33B | 74.3% | 56.4% | $9.07B | $7.39B |
| FY 2024 | $63.63B | $41.95B | 71.9% | 55.4% | $9.84B | $6.35B |
| FY 2023 | $50.91B | $40.11B | — | — | $6.41B | $5.46B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PFE // BETA 1.05
ABT // BETA 0.99